Abstract
Purpose. To evaluate the inflammatory reaction after implantation of an angle-supported foldable acrylic anterior chamber IOL for myopia correction over time. Methods. Adult individuals seeking vision correction with stable myopia >7.0 D were included. Exclusion criteria are anterior chamber depth <2.8 mm, insufficient endothelial cell density, other preexisting ocular conditions, and prior eye surgery. Laser flare photometry and slitlamp examination were performed before and up to 1 year after implantation of an AcrySof Cachet IOL (Alcon Laboratories, Forth Worth, TX, USA). Postoperative treatment comprised antibiotic eye-drops for 5 days and nonsteroidal anti-inflammatory eye-drops (NSAIDs) for 4 weeks. Results. Average laser flare values of 15 consecutive eyes of 15 patients were 8.3 ± 9.7 preoperatively and 19.0 ± 24.2 (1 day), 24.0 ± 27.5 (1 week), 17.6 ± 13.4 (1 month), 14.9 ± 15.4 (3 months), and 10.0 ± 7.0 (1 year) photon counts/ms after implantation, respectively. Slitlamp examination yielded 0 or 1+ cells (SUN classification) in every one eye throughout the follow-up period. Conclusion. Results indicate a low maximum inflammatory response and a quick recovery to a long-term safe level. The use of NSAIDs seems sufficient in routine cases, thus avoiding potential drawbacks of using corticoids.
Highlights
Complications utilizing several types of phakic intraocular lenses to correct refractive errors are rare [1]
No cells were found at 1 month and thereafter
To the best of our knowledge, this is the first study examining the inflammatory response after implantation of an AcrySof Cachet phakic intraocular lenses (pIOLs)
Summary
Complications utilizing several types of phakic intraocular lenses (pIOLs) to correct refractive errors are rare [1]. Delicate intraocular structures including the corneal endothelium, iris, crystalline lens, and the anterior chamber angle may be altered by inflammatory processes after lens implantation. Some types of anterior chamber IOLs made from silicone require the use of steroidal eye-drops for 23 months after implantation to control the inflammatory response (Figure 1). A newly developed foldable anterior chamber anglesupported IOL is called AcrySof Cachet (Alcon Laboratories, Inc., Fort Worth, USA). This model is CE-marked and currently undergoing US Food and Drug Administration (FDA) clinical investigation for the correction of moderate to high myopia [6, 7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
